Swedish pharmaceutical company OncoZenge AB (Nasdaq First North Growth Market:ONCOZ) announced on Monday that it has appointed Swedish Contract Development and Manufacturing Organisation (CDMO) Meribel Pharma Solutions, formerly Recipharm, as its CDMO for the Phase 3 clinical trial of BupiZenge, a local anaesthetic lozenge aimed at targeting oral pain.
The decision follows a refinement of the project scope in collaboration with Italian pharmaceutical company Molteni Farmaceutici, OncoZenge's pan-European licensing partner. The Phase 3 study is intended to support European regulatory approval of BupiZenge.
Meribel will handle development and production of clinical trial materials, supporting OncoZenge's Clinical Trial Application. OncoZenge cited Meribel's technical expertise, prior experience with BupiZenge formulations, and local presence in Sweden as key factors in the selection.
Akeso enrols first patient in Phase III ivonescimab trial for pancreatic cancer
AN2 Therapeutics and DNDi partner to advance oral therapy for chronic Chagas disease
Enveric Biosciences secures second US patent allowance for non-hallucinogenic mescaline derivatives
Lantern Pharma reports first complete response with LP-284 in heavily pretreated lymphoma patient
Hoth Therapeutics Ppartners with VA to evaluate GDNF for obesity and fatty liver disease
AstraZeneca announces USD50bn US investment to expand manufacturing and R&D footprint
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
AusperBio receives Chinese regulatory approval for Phase III trial of AHB-137 in chronic hepatitis B
DualityBio's HER3 ADC DB-1310 granted US FDA Fast Track Designation
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic